Pharmaxis's Bronchitol positive in Phase III for cystic fibrosis
This article was originally published in Scrip
Executive Summary
Pharmaxis's cystic fibrosis treatment, Bronchitol, has met the primary endpoint of improvement in lung function in its first Phase III study.